duloxetine has been researched along with Depression in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, HY; Carter, DS; Greenhouse, R; Iyer, PS; Lee, EK; Lin, CJ; Lucas, MC; Lynch, SM; Madera, AM; Moore, A; Ozboya, K; Schoenfeld, RC; Steiner, S; Weikert, RJ; Zhai, Y | 1 |
| Abraham, R; Bhyrapuneni, G; Bogaraju, N; Jasti, V; Mekala, VR; Mohammed, AR; Muddana, N; Nirogi, R; Palacharla, RC; Ravella, SR; Shinde, AK; Subramanian, R; Thentu, JB | 1 |
2 other study(ies) available for duloxetine and Depression
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain.
Topics: Animals; Antidepressive Agents, Tricyclic; Caco-2 Cells; Depression; Dopamine; Dopamine Uptake Inhibitors; Drug Design; Humans; Neurotransmitter Uptake Inhibitors; Norepinephrine; Pain; Pyrrolidines; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin | 2010 |
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression.
Topics: Administration, Oral; Animals; Antidepressive Agents; Bridged Bicyclo Compounds; Depression; Halogenation; Humans; Male; Nicotinic Antagonists; Pyridines; Rats; Rats, Wistar; Receptors, Nicotinic | 2020 |